This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n8http://localhost/temp/predkladatel/
n19http://linked.opendata.cz/resource/domain/vavai/projekt/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n9http://linked.opendata.cz/ontology/domain/vavai/
n14http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F02%3A00007783%21RIV08-GA0-14110___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F02%3A00007783%21RIV08-GA0-14110___
rdf:type
n9:Vysledek skos:Concept
dcterms:description
Dendritic cells (DCs) are antigen-presenting cells that play a key role in the induction of cytotoxic T-lymphocytes. Adjuvant immunotherapy with antigen-loaded DCs represents an attractive anticancer strategy for multiple myeloma (MM). Autologous DCs loaded with idiotypic protein or other myeloma-associated antigen have been used in several clinical trials. Preclinical and first clinical experience have provided valuable insights in the mechanisms of cellular immunity, but few, if any, patients with MM benefited from such vaccination. Taken together, the data suggest that antitumor T-cell responses fail in MM because of a deregulated cytokine network, downregulation of costimulatory surface receptor expression, and changes in T-cell repertoire, enabling tumor cells to escape immune effectors by preventing the antitumor immune response. We discuss current clinical protocols for DC-based immunotherapy in MM and review some strategies that may increase the efficacy of DC vaccines. Dendritic cells (DCs) are antigen-presenting cells that play a key role in the induction of cytotoxic T-lymphocytes. Adjuvant immunotherapy with antigen-loaded DCs represents an attractive anticancer strategy for multiple myeloma (MM). Autologous DCs loaded with idiotypic protein or other myeloma-associated antigen have been used in several clinical trials. Preclinical and first clinical experience have provided valuable insights in the mechanisms of cellular immunity, but few, if any, patients with MM benefited from such vaccination. Taken together, the data suggest that antitumor T-cell responses fail in MM because of a deregulated cytokine network, downregulation of costimulatory surface receptor expression, and changes in T-cell repertoire, enabling tumor cells to escape immune effectors by preventing the antitumor immune response. We discuss current clinical protocols for DC-based immunotherapy in MM and review some strategies that may increase the efficacy of DC vaccines. Dendritic cells (DCs) are antigen-presenting cells that play a key role in the induction of cytotoxic T-lymphocytes. Adjuvant immunotherapy with antigen-loaded DCs represents an attractive anticancer strategy for multiple myeloma (MM). Autologous DCs loaded with idiotypic protein or other myeloma-associated antigen have been used in several clinical trials. Preclinical and first clinical experience have provided valuable insights in the mechanisms of cellular immunity, but few, if any, patients with MM benefited from such vaccination. Taken together, the data suggest that antitumor T-cell responses fail in MM because of a deregulated cytokine network, downregulation of costimulatory surface receptor expression, and changes in T-cell repertoire, enabling tumor cells to escape immune effectors by preventing the antitumor immune response. We discuss current clinical protocols for DC-based immunotherapy in MM and review some strategies that may increase the efficacy of DC vaccines.
dcterms:title
Dendritic cell vaccines in the treatment of multiple myeloma: Advances and Limitations. Dendritic cell vaccines in the treatment of multiple myeloma: Advances and Limitations. Dendritic cell vaccines in the treatment of multiple myeloma: Advances and Limitations.
skos:prefLabel
Dendritic cell vaccines in the treatment of multiple myeloma: Advances and Limitations. Dendritic cell vaccines in the treatment of multiple myeloma: Advances and Limitations. Dendritic cell vaccines in the treatment of multiple myeloma: Advances and Limitations.
skos:notation
RIV/00216224:14110/02:00007783!RIV08-GA0-14110___
n3:strany
213-218
n3:aktivita
n15:P n15:Z
n3:aktivity
P(GA301/00/0405), Z(MZ06526970501)
n3:cisloPeriodika
4
n3:dodaniDat
n5:2008
n3:domaciTvurceVysledku
n7:9622748
n3:druhVysledku
n16:J
n3:duvernostUdaju
n18:S
n3:entitaPredkladatele
n17:predkladatel
n3:idSjednocenehoVysledku
642437
n3:idVysledku
RIV/00216224:14110/02:00007783
n3:jazykVysledku
n12:eng
n3:klicovaSlova
dendritic cells; multiple myeloma; immunotherapy; cytotoxic T-cells; tumor immunology
n3:klicoveSlovo
n4:immunotherapy n4:dendritic%20cells n4:cytotoxic%20T-cells n4:tumor%20immunology n4:multiple%20myeloma
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[56A470A4D2C8]
n3:nazevZdroje
Medical Oncology
n3:obor
n13:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
2
n3:projekt
n19:GA301%2F00%2F0405
n3:rokUplatneniVysledku
n5:2002
n3:svazekPeriodika
19/2002
n3:tvurceVysledku
Hájek, Roman Büchler, Tomáš
n3:zamer
n14:MZ06526970501
s:issn
1357-0560
s:numberOfPages
9
n8:organizacniJednotka
14110